MDxHealth, Inc. Prepares For Growth With Executive Team Expansion
Published: Sep 06, 2017
Michael K. Brawer, MD Appointed as Chief Medical Officer
PRESS RELEASE / REGULATED INFORMATION
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, September 6, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the appointment of Michael K. Brawer, MD as Chief Medical Officer in a series of executive hires to prepare the Company for growth in the second half of the year and beyond.
Dr. Brawer is an accomplished urologist and former professor of urology and pathology, with over 25 years of industry experience leading clinical affairs for urology-focused diagnostic and pharmaceutical companies.
Most recently, Dr. Brawer served as Vice President of Medical Affairs, Urology at Myriad Genetics where he led all clinical aspects of development, education and commercialization of their prognostic prostate cancer assay. Previously, Dr. Brawer held senior leadership positions for GTx Inc, Tokai Pharmaceuticals and Threshold Pharmaceuticals. Prior to his corporate career, Dr. Brawer was a practicing urologist and the Director of the Northwest Prostate Institute for almost a decade, after holding teaching positions in pathology and urology at the University of Washington and University of Arizona.
Over the first seven months of 2017, in addition to bringing on Dr. Brawer, MDxHealth has expanded its executive function with the appointment of Jean-Marc Roelandt as Chief Financial Officer, Shalon Roth as Executive Vice President of Corporate Communications & Public Affairs and Paul Marr as Executive Vice President of Sales for North America.
"MDxHealth has made industry-changing advancements to improve prostate cancer diagnosis with its portfolio of tests, and commands a leading position in molecular diagnostic testing for urology," stated Michael Brawer MD, CMO, MDxHealth. "I am thrilled to work with this highly experienced executive management and clinical affairs team to help the Company build upon its proven success in the market."
"We are excited to welcome such an accomplished medical professional to our Executive Leadership Team and are confident that Dr. Brawer's extensive industry experience will help further advance our clinical and commercial strategy," commented Dr. Jan Groen, CEO, MDxHealth. "Dr. Brawer's arrival rounds out our 2017 campaign to expand our executive team, alongside our goal to nearly double our US sales force, in preparation for a sustained growth phase."
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
Shalon Roth, EVP Corporate Communications
+44 (0)7393 906278
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners. The foregoing information on Kaiser Permanente and the General Service Administration contract awards is not intended to serve as an endorsement of MDxHealth or ConfirmMDx by Kaiser Permanente or the US Government.